Key facts
- Oncoshot’s last known valuation is $20.1M (Oct 2022).
- It has raised $5.5M; the latest was Later Stage VC in Oct 2025.
- Notable investors include MassMutual Ventures, SEEDS Capital, Crane Venture Partners, Lion City Capital, 53B — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Oncoshot
- ·The full record, as it builds
Funding rounds
No funding rounds for Oncoshot are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Oncoshot
Developer of an AI platform designed to increase cancer clinical trial success. The company's platform connects cancer hospitals and industry partners, facilitating the safe and secure exchange of information needed to support a data-driven clinical trials ecosystem, enabling regional healthcare institutions, contract research organizations, and global biotechnology and pharmaceutical companies to conduct data-driven cancer clinical trials while accelerating enrollment.
- Sector
- Healthcare
- HQ
- Singapore, Singapore
- Founded
- 2018
- Employees
- 17
- Website
- oncoshot.in/
- Ownership
- Privately Held (backing)
Oncoshot doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Oncoshot shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Oncoshot in its N-PORT filings yet. We sweep new filings monthly.